Rohto Pharmaceutical Co (TSE:4527) Cash-to-Debt : 8.50 (As of Dec. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Rohto Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Rohto Pharmaceutical Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.50.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Rohto Pharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Rohto Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

TSE:4527' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.87 Med: 4.69 Max: 12.39
Current: 8.5

During the past 13 years, Rohto Pharmaceutical Co's highest Cash to Debt Ratio was 12.39. The lowest was 1.87. And the median was 4.69.

TSE:4527's Cash-to-Debt is ranked better than
82.35% of 1853 companies
in the Consumer Packaged Goods industry
Industry Median: 0.53 vs TSE:4527: 8.50

Rohto Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Rohto Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Rohto Pharmaceutical Co Cash-to-Debt Chart

Rohto Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

7.32

6.21

6.54

3.40

6.84

Rohto Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															4.94	6.84	7.03	7.94	8.50

Competitive Comparison of Rohto Pharmaceutical Co's Cash-to-Debt

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rohto Pharmaceutical Co's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Cash-to-Debt falls into.

Rohto Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Rohto Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	79951	/	(4177	+	7516)
	=	6.84

Rohto Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	81877	/	(4359	+	5273)
	=	8.50

Rohto Pharmaceutical Co (TSE:4527) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Rohto Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Rohto Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rohto Pharmaceutical Co (TSE:4527) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rohto Pharmaceutical Co Ltd (TSE:4527) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

4527:Mexico

Address

1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka, JPN, 544-8666

Website

https://www.rohto.co.jp

Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.

Rohto Pharmaceutical Co (TSE:4527) Headlines

No Headlines